What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

Abstract:

:In the US, adverse drug reactions (ADRs) rank between the fourth to sixth leading cause of death, ahead of pneumonia and diabetes mellitus. An important reason for the high incidence of serious and fatal ADRs is that the existing drug development paradigms do not generate adequate information on the mechanistic sources of marked variability in pharmacokinetics and pharmacodynamics of new therapeutic candidates, precluding treatments from being tailored for individual patients. Pharmacogenetics is the study of the hereditary basis of person-to-person variations in drug response. The focus of pharmacogenetic investigations has traditionally been unusual and extreme drug responses resulting from a single gene effect. The Human Genome Project and recent advancements in molecular genetics now present an unprecedented opportunity to study all genes in the human genome, including genes for drug metabolism, drug targets and postreceptor second messenger machinery, in relation to variability in drug safety and efficacy. In addition to sequence variations in the genome, high throughput and genome-wide transcript profiling for differentially regulated mRNA species before and during drug treatment will serve as important tools to uncover novel mechanisms of drug action. Pharmacogenetic-guided drug discovery and development represent a departure from the conventional approach which markets drugs for broad patient populations, rather than smaller groups of patients in whom drugs may work more optimally. Pharmacogenetics provides a rational framework to minimise the uncertainty in outcome of drug therapy and clinical trials and thereby should significantly reduce the risk of drug toxicity.

journal_name

Drug Saf

journal_title

Drug safety

authors

Ozdemir V,Shear NH,Kalow W

doi

10.2165/00002018-200124020-00001

keywords:

subject

Has Abstract

pub_date

2001-01-01 00:00:00

pages

75-85

issue

2

eissn

0114-5916

issn

1179-1942

journal_volume

24

pub_type

杂志文章,评审
  • The case-population study design: an analysis of its application in pharmacovigilance.

    abstract:BACKGROUND:The case-population approach or population-based case-cohort approach is derived from the case-control design and consists of comparing past exposure to a given risk factor in subjects presenting a given disease or symptom (cases) with the exposure rate to this factor in the whole cohort or in the source pop...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11592140-000000000-00000

    authors: Théophile H,Laporte JR,Moore N,Martin KL,Bégaud B

    更新日期:2011-10-01 00:00:00

  • Epidemiology of adverse drug reactions in Europe: a review of recent observational studies.

    abstract::Adverse drug reactions (ADRs) cause considerable mortality and morbidity but no recent reviews are currently available for the European region. Therefore, we performed a review of all epidemiological studies quantifying ADRs in a European setting that were published between 1 January 2000 and 3 September 2014. Include...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-015-0281-0

    authors: Bouvy JC,De Bruin ML,Koopmanschap MA

    更新日期:2015-05-01 00:00:00

  • Dopamine Agonists and Impulse Control Disorders: A Complex Association.

    abstract::Impulse control disorders (ICDs) are a well-known adverse effect of dopamine agonists (DAAs). This critical review aims to summarize data on the prevalence and factors associated with the development of an ICD simultaneous to DAA use. A search of two electronic databases was completed from inception to July 2017. The ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-017-0590-6

    authors: Grall-Bronnec M,Victorri-Vigneau C,Donnio Y,Leboucher J,Rousselet M,Thiabaud E,Zreika N,Derkinderen P,Challet-Bouju G

    更新日期:2018-01-01 00:00:00

  • Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.

    abstract::The aim of this review is to analyse and summarise the literature data about the incidence of weight gain in patients exposed to atypical antipsychotics during long-term (>or=1 year) treatment regimens. Despite the clinical relevance of the topic, the vast majority of reviewed studies showed methodological limitations...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629040-00002

    authors: Gentile S

    更新日期:2006-01-01 00:00:00

  • Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.

    abstract::After 2002, an association between stroke and antipsychotic use was reported in clinical trials and large database studies. This review considers previous quantitative reviews, newly published clinical trials, and recent observational cohort and case-control studies, and focuses on the clinical significance of the ris...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11319120-000000000-00000

    authors: Sacchetti E,Turrina C,Valsecchi P

    更新日期:2010-04-01 00:00:00

  • Using MedDRA: implications for risk management.

    abstract::The introduction of MedDRA, the Medical Dictionary for Regulatory Activities, as a standardised terminology may have a major impact on the performance of risk management. Thus, MedDRA is likely to have an important effect on the analysis of clinical trial safety data. Review of the most commonly used terms in clinical...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200427080-00010

    authors: Brown EG

    更新日期:2004-01-01 00:00:00

  • A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool.

    abstract:INTRODUCTION:Evaluation of risk minimization (RM) actions is an emerging area of regulatory science, often without tools to rapidly and systematically assess their effectiveness. PURPOSE:The aim of this study was to evaluate whether chronographs, typically used for rapid signal detection in observational longitudinal ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00853-y

    authors: Sobel RE,Blackwell W,Fram DM,Bate A

    更新日期:2019-11-01 00:00:00

  • Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.

    abstract:BACKGROUND:While cases of amyotrophic lateral sclerosis (ALS) or ALS-like conditions have arisen in apparent association with HMG-CoA reductase inhibitors ('statins') and/or other lipid-lowering drugs (collectively termed 'statins' in this paper for brevity), additional information is needed to understand whether the c...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200932080-00004

    authors: Golomb BA,Kwon EK,Koperski S,Evans MA

    更新日期:2009-01-01 00:00:00

  • In vitro models.

    abstract::The development of in vitro models is advancing rapidly, with the application of cell culture methods as an alternative to animals in toxicological screening; non-cellular systems are also being used. Any screening test, whether for detecting irritants, carcinogens or teratogens should be well validated against known ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199000051-00006

    authors: Anderson D

    更新日期:1990-01-01 00:00:00

  • Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation.

    abstract::Drug-induced QT interval prolongation is now a major concern in safety pharmacology. Regulatory authorities such as the US FDA and the European Medicines Agency require in vitro testing of all drug candidates against the potential risk for QT interval prolongation prior to clinical trials. Common in vitro methods incl...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200427110-00002

    authors: Meyer T,Boven KH,Günther E,Fejtl M

    更新日期:2004-01-01 00:00:00

  • Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.

    abstract:BACKGROUND:Psoriasis is a chronic autoimmune disease characterized by infiltration of the dermis and epidermis by activated T cells and the hyperproliferation and abnormal differentiation of keratinocytes. It is a life-long disease with alternating periods of remission and recurrence. Efalizumab is a humanized, recombi...

    journal_title:Drug safety

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/00002018-200831080-00008

    authors: Hamilton T,Menter A,Caro I,Compton P,Sobell J,Papp KA

    更新日期:2008-01-01 00:00:00

  • Drug-induced endocrine and metabolic disorders.

    abstract::Complex interactions exist amongst the various components of the neuroendocrine system in order to maintain homeostasis, energy balance and reproductive function. These components include the hypothalamus-pituitary- adrenal and -gonadal axes, the renin-angiotensin-aldosterone system, the sympathetic nervous system and...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200730030-00005

    authors: Ma RC,Kong AP,Chan N,Tong PC,Chan JC

    更新日期:2007-01-01 00:00:00

  • Neuropsychiatric complications of antiretroviral therapy.

    abstract::Neuropsychiatric adverse effects related to potent antiretroviral therapy are among the complications that can lead to poor adherence, treatment interruptions, or change of antiretroviral therapy regimens. For a historical perspective, we review early literature and case reports with CNS adverse effects attributed to ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629100-00004

    authors: Cespedes MS,Aberg JA

    更新日期:2006-01-01 00:00:00

  • Current challenges and controversies in drug-induced liver injury.

    abstract::Current key challenges and controversies encountered in the identification of potentially hepatotoxic drugs and the assessment of drug-induced liver injury (DILI) are covered in this article. There is substantial debate over the classification of DILI itself, including the definition and validity of terms such as 'int...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03261997

    authors: Corsini A,Ganey P,Ju C,Kaplowitz N,Pessayre D,Roth R,Watkins PB,Albassam M,Liu B,Stancic S,Suter L,Bortolini M

    更新日期:2012-12-01 00:00:00

  • Safety of clopidogrel and aspirin for stroke prevention: implications of the CHARISMA trial.

    abstract::Antiplatelet therapy is universally recommended for the prevention of recurrent events in patients with noncardioembolic ischaemic stroke or transient ischaemic attack (TIA), acute and chronic coronary artery disease, or peripheral arterial disease. However, choosing which antiplatelet agents to use in these situation...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200831060-00001

    authors: Ruland S

    更新日期:2008-01-01 00:00:00

  • Risk-benefit assessment of opioids in chronic noncancer pain.

    abstract::Opioids have been accepted as appropriate treatment for acute and cancer pain, but their role in the management of chronic nonmalignant pain is the subject of much debate, mainly due to concerns about waning efficacy, the potential for neuropsychological impairment and the development of drug addiction. Controlled cli...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199921040-00004

    authors: Bannwarth B

    更新日期:1999-10-01 00:00:00

  • Quinolones: review of psychiatric and neurological adverse reactions.

    abstract::Quinolones are a class of antibacterial agents for the treatment of several infectious diseases (e.g. urinary and respiratory tract infections). They are used worldwide due to their broad spectrum of activity, high bioavailability and good safety profile. The safety profile varies from quinolone to quinolone. The aim ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11587280-000000000-00000

    authors: Tomé AM,Filipe A

    更新日期:2011-06-01 00:00:00

  • Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).

    abstract:INTRODUCTION:Pharmacovigilance includes analysis of large databases of information on drugs and events using algorithms that detect disproportional frequencies of associations. In order to test such algorithms, attempts have been made to provide canonical reference lists of so-called 'positive controls' and 'negative c...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0392-2

    authors: Hauben M,Aronson JK,Ferner RE

    更新日期:2016-05-01 00:00:00

  • Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands.

    abstract:BACKGROUND:The tumour necrosis factor-alpha inhibitor infliximab is incorporated in the treatment guidelines for patients with inflammatory bowel disease (IBD). However, concerns about serious adverse events such as infections, malignancies and death do exist. OBJECTIVE:To evaluate the occurrence of serious events of ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/0002018-200831120-00009

    authors: de Vries HS,van Oijen MG,de Jong DJ

    更新日期:2008-01-01 00:00:00

  • Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.

    abstract::Randomized controlled trials always report the dose assessed and usually include a measure of adherence. By comparison, observational studies assessing medication safety often fail to report the dose used and rarely report any measure of adherence to therapy. This limits the ability to control for differences in doses...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-015-0347-z

    authors: Roughead EE,Pratt NL

    更新日期:2015-12-01 00:00:00

  • Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

    abstract::Cholinesterase inhibitors are currently the most established treatment strategy in Alzheimer's disease. The treatment effect appears mainly to be symptomatic. Effects on progression of the disease following long term treatment, and possible neuroprotective effects, have been investigated. Delay until nursing home plac...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199819060-00004

    authors: Nordberg A,Svensson AL

    更新日期:1998-12-01 00:00:00

  • Post-approval safety issues with innovative drugs: a European cohort study.

    abstract:BACKGROUND:At time of approval, knowledge of the full benefit risk of any drug is limited, in particular with regards to safety. Post-approval surveillance of potential drug safety concerns is recognized as an important task of regulatory agencies. For innovative, often first-in-class drugs, safety knowledge at time of...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0094-y

    authors: Mol PG,Arnardottir AH,Motola D,Vrijlandt PJ,Duijnhoven RG,Haaijer-Ruskamp FM,de Graeff PA,Denig P,Straus SM

    更新日期:2013-11-01 00:00:00

  • Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

    abstract::Pharmacovigilance science has traditionally been a discipline focussed on the postmarketing or post-authorisation period, with due attention directed towards pre-clinical safety data, clinical trials and adverse events. As the biological sciences have evolved, pharmacovigilance has slowly shifted toward earlier, proac...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629080-00003

    authors: Hartford CG,Petchel KS,Mickail H,Perez-Gutthann S,McHale M,Grana JM,Marquez P

    更新日期:2006-01-01 00:00:00

  • The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients.

    abstract:BACKGROUND AND OBJECTIVE:Many drugs that are used to treat children are either not licensed for use in paediatric patients (unlicensed) or prescribed outside the terms of the product licence (off label). The incidence of adverse drug reactions (ADRs) associated with the use of such drugs is yet to be established. This ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200427130-00006

    authors: Neubert A,Dormann H,Weiss J,Egger T,Criegee-Rieck M,Rascher W,Brune K,Hinz B

    更新日期:2004-01-01 00:00:00

  • A risk-benefit assessment of anti-obesity drugs.

    abstract::This review evaluates the benefits and potential health risks of the currently used drugs that are approved for the pharmacological treatment of obesity. Analysis of several long term clinical trials indicates that all of these drugs are efficient in reducing excess bodyweight, and that the majority of them allow the ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199920020-00003

    authors: Kolanowski J

    更新日期:1999-02-01 00:00:00

  • Predictors and timing of adverse experiences during trandsdermal nicotine therapy.

    abstract:OBJECTIVES:Difficulty sleeping is a recognised tobacco withdrawal symptom, but sleep problems, like application site reactions, are commonly reported as adverse reactions to transdermal nicotine therapy. However, no studies have examined potential predictive factors associated with the occurrence of expected adverse ex...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-199920060-00007

    authors: Gourlay SG,Forbes A,Marriner T,McNeil JJ

    更新日期:1999-06-01 00:00:00

  • Correction to: vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues.

    abstract::The article vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues, written by Tomas Bergvall. G. Niklas Norén. Marie Lindquist, was originally published Online First without open access. ...

    journal_title:Drug safety

    pub_type: 已发布勘误

    doi:10.1007/s40264-019-00803-8

    authors: Bergvall T,Norén GN,Lindquist M

    更新日期:2019-06-01 00:00:00

  • Safety and Tolerability of Adoptive Cell Therapy in Cancer.

    abstract::Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] eng...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0779-3

    authors: Wolf B,Zimmermann S,Arber C,Irving M,Trueb L,Coukos G

    更新日期:2019-02-01 00:00:00

  • Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.

    abstract::Boxed warnings-also known as "black box" warnings-can be a powerful tool in communicating drug risks to physicians and patients. The overall number of boxed warnings has grown in recent years as the US Food and Drug Administration (FDA) has approved more drugs on the basis of limited pre-marketing information and as n...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0419-8

    authors: Yeh JS,Sarpatwari A,Kesselheim AS

    更新日期:2016-08-01 00:00:00

  • Adverse effects of monobactams and carbapenems.

    abstract::Monobactams and carbapenems are 2 classes of beta-lactam antibiotics that were introduced in the 1980s. This review considers the monobactam aztreonam and the carbapenems imipenem and meropenem. Imipenem is administered together with cilastatin, which inhibits the enzymatic breakdown of imipenem in the kidney. The ant...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199512050-00003

    authors: Alván G,Nord CE

    更新日期:1995-05-01 00:00:00